XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) - USD ($)
Total
Common Stock
Additional Paid-in Capital
Subscription Receivable
Accumulated Deficit
Beginning balances (in shares) at Dec. 31, 2023   24,508,795      
Beginning balances at Dec. 31, 2023 $ (4,033,406) $ 2,450 $ 64,468,141 $ (169,616) $ (68,334,381)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of warrants (in shares)   125,000      
Exercise of warrants 5,832 $ 12 5,820    
Interest on recourse loan 3,987     3,987  
Stock-based compensation 4,255,432   4,255,432    
Net loss (9,037,971)       (9,037,971)
Ending balances (in shares) at Mar. 31, 2024   24,633,795      
Ending balances at Mar. 31, 2024 (8,806,126) $ 2,462 68,729,393 (165,629) (77,372,352)
Beginning balances (in shares) at Dec. 31, 2024   51,288,566      
Beginning balances at Dec. 31, 2024 131,680,914 $ 5,127 239,201,220 0 (107,525,433)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock, net of offering costs (in shares)   4,210,525      
Issuance of common stock, net of offering costs 75,846,941 $ 421 75,846,520    
Short-swing profit disgorgement 47,970   47,970    
Vested restricted stock units (in shares)   121,660      
Vested restricted stock units   $ 12 (12)    
Exercise of warrants (in shares)   1,164,644      
Exercise of warrants $ 11,787,204 $ 116 11,787,088    
Exercise of options (in shares) 60,120 60,120      
Exercise of options $ 137,564 $ 6 137,558    
Stock-based compensation 3,879,367   3,879,367    
Net loss (13,216,292)       (13,216,292)
Ending balances (in shares) at Mar. 31, 2025   56,845,515      
Ending balances at Mar. 31, 2025 $ 210,163,668 $ 5,682 $ 330,899,711 $ 0 $ (120,741,725)